Cardiac hypertrophy: Targeting Raf/MEK/ERK1/2-signaling

被引：106
|
作者：
Lorenz, Kristina [1 ]
Schmitt, Joachim P. [1 ]
Vidal, Marie [1 ]
Lohse, Martin J. [1 ,2 ]
机构：
[1] Univ Wurzburg, Inst Pharmacol & Toxicol, D-97078 Wurzburg, Germany
[2] Univ Wurzburg, Rudolf Virchow Ctr, DFG Res Ctr Expt Biomed, D-97078 Wurzburg, Germany
来源：
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY | 2009年 / 41卷 / 12期
关键词：
Cardiac hypertrophy; ERK1/2; Signaling; ACTIVATED PROTEIN-KINASE; EXTRACELLULAR SIGNAL; DIFFERENTIAL REGULATION; DILATED CARDIOMYOPATHY; INDUCED APOPTOSIS; HEART; INHIBITION; PATHWAY; DYSFUNCTION; MECHANISMS;
D O I：
10.1016/j.biocel.2009.08.002
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Over the past two decades, basic research has revealed a complex network of regulatory mechanisms that control the ERK1/2-signaling cascade. ERK1/2 mediate cardiac hypertrophy, a major risk factor for the development of arrhythmias, heart failure and sudden death, but also beneficial effects, e.g. protection of the heart from cell death and ischemic injury. Selective targeting of these ambiguous ERK functions could provide a powerful tool in the treatment of cardiac disease. This short review will discuss new mechanistic insights into ERK1/2-dependent development of cardiac hypertrophy and the prospect to translate this knowledge into future therapeutic strategies. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码：2351 / 2355
页数：5
相关论文
共 50 条
  • [31] Shear Stress-Induced Activation of Raf/MEK/ERK1/2 Signaling Contributes to tPA Expression in Human Endothelial Progenitor Cells
    Tao, Jun
    Yang, Zhen
    Xia, Wenhao
    Yu, Bingbo
    Qiu, Yanxia
    CIRCULATION, 2011, 124 (21)
  • [32] SIMULTANEOUS TARGETING OF RAF, MEK, AND ERK LIMITS DRUG RESISTANCE
    CANCER DISCOVERY, 2017, 7 (09) : 931 - 931
  • [33] Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy
    R Mandal
    S Becker
    K Strebhardt
    Oncogene, 2016, 35 : 2547 - 2561
  • [34] Targeting the RAF-MEK-ERK pathway in cancer therapy
    Montagut, Clara
    Settleman, Jeff
    CANCER LETTERS, 2009, 283 (02) : 125 - 134
  • [35] Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy
    Mandal, R.
    Becker, S.
    Strebhardt, K.
    ONCOGENE, 2016, 35 (20) : 2547 - 2561
  • [36] Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma
    Yang, Sufang
    Liu, Guohua
    ONCOLOGY LETTERS, 2017, 13 (03) : 1041 - 1047
  • [37] Raf but not mek and ERK1/ERK2 is involved in IL-1beta-induced expression of iNOS in human primary astrocytes
    Liu, X
    Saha, RN
    Jana, M
    Pahan, K
    JOURNAL OF NEUROCHEMISTRY, 2003, 85 : 15 - 15
  • [38] AMPK activation enhances PPARα activity to inhibit cardiac hypertrophy via ERK1/2 MAPK signaling pathway
    Meng, Rongsen
    Pei, Zhaohui
    Zhang, Aixia
    Zhou, Yutian
    Cai, Xingming
    Chen, Baolin
    Liu, Guanjie
    Mai, Weiyi
    Wei, Jianrui
    Dong, Yugang
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2011, 511 (1-2) : 1 - 7
  • [39] Calcineurin and Erk1/2-signaling pathways are involved in the antiapoptotic effect of cyclosporin A on astrocytes exposed to simulated ischemia in vitro
    Gabryel, Bozena
    Pudelko, Anna
    Adamczyk, Jakub
    Fischer, Ireneusz
    Malecki, Andrzej
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2006, 374 (02) : 127 - 139
  • [40] Calcineurin and Erk1/2-signaling pathways are involved in the antiapoptotic effect of cyclosporin A on astrocytes exposed to simulated ischemia in vitro
    Bozena Gabryel
    Anna Pudelko
    Jakub Adamczyk
    Ireneusz Fischer
    Andrzej Malecki
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2006, 374 : 127 - 139
12345